UNSPSC 51314362: Dexchlorpheniramine/guaifenesin/pseudoephedrine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE503. This VA Drug Class (RE503) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT/EXPECTORANT.

UNSPSC 51314362 Dexchlorpheniramine/guaifenesin/pseudoephedrine is a Commodity code that in recent state and local procurement appears to span a broader range of pharmaceutical and health product procurement than its nominal chemical compound name suggests. State and local buyers soliciting under this code are acquiring naloxone and drug deactivation systems, generic multi-source pharmaceuticals, and over-the-counter products through various purchasing mechanisms. The issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas Health and Human Services Commission), and cooperative purchasing alliances serving multiple state and local jurisdictions (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). The scope reflects both direct county-level procurement for community health initiatives and large-scale cooperative purchasing vehicles that consolidate demand across participating state and local government facilities.

Recent activity centers on Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to explore vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions program aimed at improving pharmacy benefit efficiency. The Minnesota Department of Administration issued RFP S1070000015802 through MMCAP in January 2026 to establish multiple contracts for generic pharmaceuticals and OTC products distributed across participating state and local government facilities in Minnesota and Oregon, with proposals due March 26, 2026 and contract awards effective July 1, 2026. Vendors responding to the MMCAP RFP must maintain relationships with authorized wholesalers, certify cGMP and Drug Supply Chain Security Act compliance, and carry insurance including $5 million commercial general liability coverage.